NCT07482917 Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
| NCT ID | NCT07482917 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital de Granollers |
| Condition | Interstitial Lung Disease (ILD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 92 participants |
| Start Date | 2026-03-09 |
| Primary Completion | 2028-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 92 participants in total. It began in 2026-03-09 with a primary completion date of 2028-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD). In routine clinical practice, diagnostic workflows for ILD are frequently fragmented, involving multiple independent appointments that can lead to significant delays and increased burden for patients and caregivers. This study compares the standard diagnostic pathway against an optimized circuit where core diagnostic procedures-such as high-resolution CT, pulmonary function tests, and laboratory panels-are pre-bundled and scheduled within a coordinated and compressed timeframe. All eligible patients referred for suspected ILD are included consecutively to ensure a pragmatic, real-world representation of the referral population. The primary objective is to measure the time to diagnostic communication, defined as the duration from randomization to the date the patient is formally informed of the final diagnosis following a multidisciplinary team (MDT) consensus. Secondary objectives include assessing the time to MDT diagnosis, the time to treatment initiation (when clinically indicated), socioeconomic cost-burden, and the environmental carbon footprint of the diagnostic journey. Furthermore, the study evaluates health-related quality of life, psychological distress, and clinical frailty, while exploring factors such as language proficiency as determinants of diagnostic equity. Caregiver-related outcomes, including burden and experience measures, are contingent upon the presence of a primary caregiver and the provision of their independent informed consent. The design of this protocol was informed by a patient focus group and is officially endorsed by the 'AIRE' Associació Catalana de Malalts i Trasplantats Pulmonars, ensuring a patient-centered approach that prioritizes the diagnostic journey's efficiency and human impact.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older. * Referral for suspected or undiagnosed interstitial lung disease (ILD). * At least one of the following: * A finding suggestive of ILD (such as reticulation, ground-glass opacities, traction bronchiectasis or honeycombing) not attributable to another disease, on a CT available at referral that includes the lung parenchyma, regardless of its indication; or * Persistent or progressive shortness of breath or chronic cough not attributable to another disease, accompanied by at least one of the following: an interstitial or reticular pattern on chest radiograph; reduced forced vital capacity; persistent bibasilar crackles or digital clubbing; a relevant environmental or occupational exposure, autoimmune disease, or suspected drug or radiation toxicity; or a first-degree family history of ILD. * Ability to provide informed consent. Exclusion Criteria: * Complete ILD diagnostic work-up already performed (chest CT plus full pulmonary function testing including six-minute walk test plus complete ILD laboratory panel). * Established diagnosis of ILD previously assigned by another center or specialist. * Clinical instability or acute illness that would prevent reliable completion of diagnostic procedures (e.g., respiratory infection, suspected acute ILD exacerbation, acute heart failure). * Acute iatrogenic pneumonitis (drug-, chemotherapy- or radiation-induced) with a clear temporal relationship to the offending agent. * Medical, functional, psychiatric or logistical limitations that, in the investigators' opinion, would interfere with the diagnostic process or data collection. * Participation in another interventional clinical trial that may alter the frequency or timing of diagnostic procedures. * Cognitive impairment that prevents informed consent or completion of study questionnaires. * Refusal to participate or to allow the collection or use of clinical data.
Contact & Investigator
Jaume Bordas-Martinez, MD, PhD
PRINCIPAL INVESTIGATOR
Hospital General de Granollers
Frequently Asked Questions
Who can join the NCT07482917 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Interstitial Lung Disease (ILD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07482917 currently recruiting?
Yes, NCT07482917 is actively recruiting participants. Visit ClinicalTrials.gov or contact Hospital de Granollers to inquire about joining.
Where is the NCT07482917 trial being conducted?
This trial is being conducted at Granollers, Spain.
Who is sponsoring the NCT07482917 clinical trial?
NCT07482917 is sponsored by Hospital de Granollers. The principal investigator is Jaume Bordas-Martinez, MD, PhD at Hospital General de Granollers. The trial plans to enroll 92 participants.